ARCHIVES

Partial Responses To Zactima In Thyroid Cancer Trial

This article is from The Cancer Letter archive.

Vol. 29 No. 1 | January 27, 2006

Download PDF Visit The Full Archive

Related Articles

Fragmin Cuts Risk Of VE By 50 Percent In Study

January 31, 2003

In Brief: NSABP Selects 193 Institutions For STAR; ACR Names Evens, Ramsey As New Officers

October 9, 1998

After the Plenary: Don Berry: In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant

July 11, 2014

Ford To Resubmit Budget Slash Of $125 Million For NCI

January 3, 1975

Funding Opportunities: CAM Research Center Applications Sought.

January 3, 2003

More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene

August 28, 2009